Labor Dept. officially withdraws rule to define independent contractor within FLSA
The Department of Labor is officially withdrawing a late-Trump-era rulemaking that would have clarified the definition of what it means to be an
independent contractor within the Fair Labor Standards Act. Because the rule never took effect, owner-operators will see no changes as a result of the rule s withdrawal.
DOL published the final rule on Jan. 7, shortly before the end of Trump’s presidency. Just days prior to the rule’s publication, the incoming Biden administration specifically mentioned the independent contractor rule as one of Trump’s “midnight regulations” that would be halted.
6303 and 6505 Blue Lagoon Drive with RealOp Investments CEO Reggie Bell (Google Maps, LinkedIn)
RealOp Investments paid $110.1 million for three office buildings at the Waterford Business District near Miami International Airport.
The Greenville, South Carolina-based commercial real estate investor bought the Waterford Atrium complex at 6100, 6303 and 6505 Blue Lagoon Drive in two deals from different affiliates of MetLife, records show.
RealOp secured a $93.9 million acquisition loan from Forethought Life Insurance Company, according to a mortgage.
Waterford Atrium, built in the early 1990s, totals 498,073 square feet of office space, according to property records. It’s 71 percent leased, with tenants including the Discovery entertainment company and L’Oréal.
Zacks Investment Research was for earnings of
$1.07 per share.
$320.3 million in the period.
Ingevity expects full-year revenue in the range of
$1.27 billion to
$1.33 billion.
Ingevity shares have climbed slightly since the beginning of the year. In the final minutes of trading on Wednesday, shares hit
$75.85, an increase of 78% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from
Zacks Investment Research. Access a
Copyright by Automated Insights, Inc. All rights reserved., source
Associated Press News
05:43p
(0)
Elastrin Therapeutics Inc., a privately held biotechnology company leveraging a platform technology to develop therapeutics that render calcified tissue and organs supple again, announced the appointment of Pedro M. Quintana Diez, MD as Chief Medical Officer. Pedro will be responsible for the clinical and regulatory strategy, planning, and execution of the company s clinical development plans. We are delighted to bring someone with Pedro s impressive expertise and experience on board during this exciting time for Elastrin, said Dr. Matthias Breugelmans, CEO at Elastrin Therapeutics. His deep knowledge of cardiovascular research and medicine from both an industry and academic perspective is a strong addition to Elastrin preparing for clinical trials. His experience developing early-stage programs into commercial products will be instrumental developing our novel therapies to reverse cardiovascular disease during the next years declared Prof. Naren Vyavahare, Chief Scientifi
North Carolina man to run 750 miles across the Carolinas to raise $50K for autism einnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from einnews.com Daily Mail and Mail on Sunday newspapers.